Working… Menu

Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2 (HEPVACHIV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00451984
Recruitment Status : Unknown
Verified October 2007 by Aalborg University Hospital.
Recruitment status was:  Recruiting
First Posted : March 26, 2007
Last Update Posted : November 1, 2007
Information provided by:
Aalborg University Hospital

Brief Summary:
The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.

Condition or disease Intervention/treatment Phase
HIV Infections Hepatitis A Hepatitis B Biological: Twinrix Biological: interleukin-2 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Study Start Date : March 2007

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Antibody response to hepatitis A and hepatitis B

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion Criteria:

  • Prior hepatitis A or B

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00451984

Layout table for location contacts
Contact: Henrik Nielsen, MD, DMSci +45-99326525

Layout table for location information
Department of Infectious Diseases, Aalborg Hospital Recruiting
Aalborg, Denmark, DK9000
Principal Investigator: Raquel M Iguacel, MD         
Sub-Investigator: Henrik Nielsen, MD, DMSci         
Department of Infectious Diseases, Skejby Hospital Not yet recruiting
Aarhus, Denmark, DK8200
Contact: Alex Laursen, MD, DMSci    +45-89495566      
Principal Investigator: Ole Søgaard, MD         
Sponsors and Collaborators
Aalborg University Hospital
Layout table for investigator information
Study Chair: Henrik Nielsen, MD, DMSci Aalborg Hospital, DK-9000 Aalborg, Denmark
Layout table for additonal information Identifier: NCT00451984    
Other Study ID Numbers: VN2005/32
First Posted: March 26, 2007    Key Record Dates
Last Update Posted: November 1, 2007
Last Verified: October 2007
Keywords provided by Aalborg University Hospital:
treatment experienced
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
HIV Infections
Acquired Immunodeficiency Syndrome
Hepatitis B
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Lentivirus Infections
Retroviridae Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Hepadnaviridae Infections
DNA Virus Infections
Antineoplastic Agents
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs